Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Common RSV vaccine side effects include injection site pain, redness or swelling, fatigue, headache, muscle or joint aches, and sometimes a low-grade fever, and most resolve within a few days. Less common but more serious reactions have been reported, including allergic reactions and rare neurologic events such as Guillain-Barré syndrome, so timing, age, pregnancy status, and your health history all matter. There are several important factors to consider before and after vaccination, including which RSV vaccine you received and which symptoms warrant prompt medical attention. See below to understand more about how long side effects typically last, how to ease them safely, and the warning signs that are not normal.
If you are feeling unwell after an RSV vaccine and are unsure whether it is a routine reaction or something that needs care, a free, instant, online symptom check can help you compare your symptoms against thousands of conditions in minutes, clarify what is likely happening, and show you whether to rest at home, call your clinician, or seek urgent care right away.
Last reviewed for medical accuracy: 09/23/2025
Respiratory Syncytial Virus (RSV) can cause serious respiratory infections, especially in infants, older adults, and people with weakened immune systems. Vaccination against RSV offers significant protection, but like any medical intervention, it carries potential side effects. Understanding these rsv vaccine side effects can help you make an informed decision and manage any discomfort that might arise.
Several RSV vaccines have been authorized for use in older adults and pregnant individuals to protect newborns through transferred antibodies. Clinical trials and post-marketing surveillance provide data on safety and tolerability. Most people experience only mild reactions that resolve quickly.
These reactions are the most frequently reported. They typically appear within a day of vaccination and last one to three days.
These occur in a smaller percentage of vaccine recipients. They may require simple at-home remedies.
Serious complications are very uncommon. Vaccine trials and monitoring systems show these events occur in fewer than one in several thousand people.
If you experience any of these serious signs, seek immediate medical attention.
Most rsv vaccine side effects are mild and manageable at home with these steps:
While most reactions are mild, contact your healthcare provider or seek emergency care if you experience:
If you’re unsure whether your symptoms are normal or you need professional advice, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide whether to seek immediate medical care or manage your symptoms at home.
The primary goal of RSV vaccination is to prevent severe illness, hospitalizations, and even death related to RSV infection. While rsv vaccine side effects can be uncomfortable, the risk of serious disease often outweighs these temporary reactions. Discuss your individual risk profile—age, underlying health conditions, pregnancy status—with your doctor to decide if RSV vaccination is right for you.
Your health is unique. If you have questions about rsv vaccine side effects, underlying conditions, or whether the vaccine fits your situation, speak to a doctor. They can provide personalized advice, evaluate any potential risks, and guide you through the decision-making process.
This information is intended to help you understand the possible side effects of the RSV vaccine and how to handle them. Always reach out to a medical professional if you encounter anything serious or life-threatening. Your healthcare provider is the best resource for tailored, evidence-based guidance.
(References)
* Qiu X, Xu S, Lu Y, Luo Z, Yan Y, Wang C, Ji J. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022 Dec;68:37-53. doi: 10.1016/j.cytogfr.2022.10.001. Epub 2022 Oct 13. PMID: 36280532.
* Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V, AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. PMID: 36791160.
* Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Rämet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B, RENOIR Clinical Trial Group. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5. PMID: 37018468.
* Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, Gurtman A, MATISSE Study Group. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.
* Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PMID: 38253338; PMCID: PMC1175669.
* Phijffer EW, de Bruin O, Ahmadizar F, Bont LJ, Van der Maas NA, Sturkenboom MC, Wildenbeest JG, Bloemenkamp KW. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2. Epub 2024 May 2. PMID: 38695784; PMCID: PMC11064886.
* Roman F, Burny W, Ceregido MA, Laupèze B, Temmerman ST, Warter L, Coccia M. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev Vaccines. 2024 Jan-Dec;23(1):715-729. doi: 10.1080/14760584.2024.2382725. Epub 2024 Aug 5. PMID: 39042099.
* Simões EAF, Pahud BA, Madhi SA, Kampmann B, Shittu E, Radley D, Llapur C, Baker J, Pérez Marc G, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Padilla MD, Richmond PC, Sarwar UN, Baber J, Koury K, Lino MM, Kalinina EV, Li W, Cooper D, Anderson AS, Swanson KA, Gurtman A, Munjal I, MATISSE (Maternal Immunization Study for Safety and Efficacy) Clinical Trial Group. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 1;145(2):157-167. doi: 10.1097/AOG.0000000000005816. Epub 2025 Jan 2. PMID: 39746212; PMCID: PMC11731064.
* Kelleher K, Subramaniam N, Drysdale SB. The recent landscape of RSV vaccine research. Ther Adv Vaccines Immunother. 2025;13:25151355241310601. doi: 10.1177/25151355241310601. Epub 2025 Jan 10. PMID: 39802673; PMCID: PMC11724408.
* Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, Fleming DF, Holmes EJ, Moat LE, Redepenning SG, Smith EA, Stoddart CJ, Sundaram ME, Ulrich AK, Alba C, Anderson CJ, Arpey MK, Borre E, Ladines-Lim J, Mehr AJ, Rich K, Watts C, Basta NE, Jarolimova J, Walensky RP, Dugdale CM. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025 Dec 4;393(22):2221-2242. doi: 10.1056/NEJMsa2514268. Epub 2025 Oct 29. PMID: 41160817.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.